Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept;Atención farmacéutica a pacientes con artritis reumatoide y psoriásica en tratamiento con etanercept

Farmacia Hospitalaria

Volumn 29, Issue 3, 2005, Pages 171-176

  Romero Crespo, I ^a   Anton Torres R ^a   Borrás Blasco, Joaquín ^a   Navarro Ruiz, A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Adverse events; Etanercept; Pharmaceutical care; Psoriasic arthritis; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; HEADACHE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; NAUSEA; PATIENT CARE; PATIENT INFORMATION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

EID: 23644451808     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-6343(05)73659-x     Document Type: Article

References (32)

1. Harris ED. Rheumatoid arthritis: pathophysiology and implication for therapy. N Engl J Med 1990; 322: 1227-89.
2. Carmona I, Ballina J, Gabrial R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001; 60: 1040-5.
3. Scarpa R, Oriente P, Pucino A, Torrella M, Vignone L, Riccio A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246-50.
4. Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis: dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989; 146: 69-71.
5. Espinoza LR, Cuellar ML, Silveira LH. Psoriatic artritis. Curr Opin Rheumatol 1992; 4: 470-8.
6. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted Country, Minesota, USA, 1982-1991. J Rheumatol 2000; 27: 1247-50.
7. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96.
8. Comité de expertos de la Sociedad Española de Reumatología. Miembros del Panel. Actualización del consenso de la SER sobre la terapia con agentes inhibidores del TNF en la AR. Rev Esp Reumatol 2002; 29: 51-5.
9. Martín Alcalde E, Cantero Blanco S, Sánchez García FJ, Gómez Castillo JJ. Nuevas perspectivas en el tratamiento de la artritis reumatoide. Farm Hosp 2003; 27: 360-70.
10. Moreno R, Criado MT, Carrasco A, Coloma R. Seguimiento farmacéuticco del tratamiento con etanercept. Farm Hosp 2004; 28: 12-3.
11. Ruiz I, Salsamendi JL, Tirapu B, Alfaro J. Desarrollo de un protocolo de prescripción de medicamentos biológicos en pacientes con artritis reumatoide. Farm Hosp 2004; 28: 14.
12. Porta A, Mauriz MJ, Rodríguez MT, Freire M. Atención farmacéutica en pacientes reumatológicos en tratamiento con etanercept. Farm Hosp 2004; 28: 16-7.
13. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methrotexate. N Engl J Med 1999; 340: 253-9.
14. Lovel DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-9.
15. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis; a randomised trial. Lancet 2000; 356: 385-90.
16. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis. Arthritis and Rheumatism 2004; 50: 2264-72.
17. Panorama Actual del Medicamento (PAM) 2000. Reacciones hematológicas y alteraciones del SNC con etanercept (Enbrel®).
18. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337: 141-7.
19. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
20. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 2000; 343: 1586-93.
21. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Eng J Med 2000; 343: 1594-602.
22. Weinblatt ME, Keystone EC, Furst D, Moreland LW, Weisman MH, Birbara CA, et al. The ARMADA trial: a double blind placebo controlled trial of the fully human antiTNF monoclonal antibody, adalimumab (ED27) in patients with active RA on methotrexate (MTX). Arthritis Rheum 2003; 48: 35-45.
23. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoidarthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
24. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39: 2013-20.
25. Frediksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dematologica 1978; 157: 238-44.
26. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-81.
27. Cuellar ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23: 797-809.
28. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davis D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990; 29: 46-9.
29. Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, et al. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2001; 60 (Supl. III): 2-5.
30. Emery P, Reginster JY, Appelboom T, Breedveld FC, Edelman E, Kekow J, et al. WHO collaborating center consensus meeting on anticytokine therapy in rheumatoid arthritis. Rheumatology 2001; 40: 699-702.
31. Yazici Y, Erkan D, Paget S. Monitoring rheumatologists for methotrexate-, Etanercept-, Infliximab-Anakinra-Associated Adverse Events. Arthritis and Rheumatism 2003; 48: 2769-72.
32. Feltelius N, Fored M, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide post-marketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis Published Online First 2004. Available at: doi:10.1136/ard.2004.023473.